6563

Aurobindo Pharma gets USFDA nod for anti-migraine tablets

The annual sale of the product was around $300 mn for 12 months ending March 2012
PTI Mail Me
Comment E-mail Print Share
First Published: Tue, Jan 01 2013. 03 56 PM IST
The product which was tentatively approved by the FDA earlier, is ready for launch, a statement from Aurobindo said. Photo: Pradeep Gaur/Mint
The product which was tentatively approved by the FDA earlier, is ready for launch, a statement from Aurobindo said. Photo: Pradeep Gaur/Mint
Updated: Wed, Jan 02 2013. 12 02 AM IST
Hyderabad: Drug maker Aurobindo Pharma Ltd on Tuesday said it has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Rizatriptan Benzoate Tablets used in the treatment of migraine.
The product which was tentatively approved by the FDA earlier, is ready for launch, a statement from Aurobindo said. Rizatriptan Benzoate Tablets 5mg (base) and 10mg (base) is the generic equivalent of Merck and Co.’s Maxalt Tablets of equivalent dose and is indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old.
The annual sale of the product was approximately $300 million for 12 months ending March 2012 according to IMS data, the release said.
The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad. Aurobindo now has a total of 171 abbreviated new drug application (ANDA) approvals (146 Final approvals including 2 from Aurolife Pharma LLC and 25 Tentative approvals) from USFDA, according to Aurobindo. Aurobindo scrip ended up 2.61% at Rs 194.25 apiece on BSE on Tuesday.
Comment E-mail Print Share
First Published: Tue, Jan 01 2013. 03 56 PM IST
blog comments powered by Disqus
  • Wed, Apr 16 2014. 06 11 PM
  • Wed, Apr 09 2014. 05 19 PM
ALSO READ close

Revival of Europe business key for Aurobindo Pharma

Subscribe |  Contact Us  |  mint Code  |  Privacy policy  |  Terms of Use  |  Advertising  |  Mint Apps  |  About HT Media  |  Jobs
Contact Us
Copyright © 2014 HT Media All Rights Reserved